Remedium Lifecare Posts Strong Q2 And H1 Growth Momentum

18 Nov 2025 CW Team

For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26.

For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025.

Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth.

Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities.

The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business

Remedium Lifecare Limited has announced its consolidated financial results for the quarter and half-year ended 30 September 2025, reporting strong operational momentum and continued progress in business expansion. For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26. For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025. Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth. Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities. The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business

Infrastructure Urban

18 Nov 2025

PTC Expands Mehsana Plant To Boost Precision Manufacturing

PTC Industries Limited, a leading producer of high-precision castings and advanced materials for critical applications, has commenced a significant expansion of its investment-casting facility in Mehsana, Gujarat. With global supply chains undergoing a strategic realignment, industries are increasingly shifting production to resilient and trusted destinations. India is emerging as a major hub for precision manufacturing, creating substantial opportunities for industrial casting exports. In response, PTC is scaling and modernising its Mehsana site to capture rising global demand. The expansio..

Infrastructure Urban

18 Nov 2025

Apollo Completes Acquisition Of IDL Explosives

Apollo Defence Industries Private Limited, a subsidiary of Apollo Micro Systems Limited, has confirmed the successful completion of its full acquisition of IDL Explosives Limited from GOCL Corporation Limited. With this transaction now concluded, IDL Explosives becomes a step-down subsidiary of Apollo Micro Systems. IDL Explosives operates manufacturing facilities in Rourkela and several other locations across India. Apollo Group plans to expand and strengthen the company’s operations in line with its strategic ambitions within the rapidly growing defence explosives sector. The acquisition..

Infrastructure Urban

18 Nov 2025

GOCL Completes Sale Of IDL Explosives To Apollo Defence

GOCL Corporation Limited has announced the completion of the sale of its subsidiary, IDL Explosives Limited, to Apollo Defence Industries, marking the conclusion of the divestment process approved by shareholders earlier this year. IDL Explosives operates manufacturing units in Rourkela and several other locations nationwide. Apollo Defence plans to expand and reinforce the business in line with its strategic objectives within the rapidly growing defence sector. With this divestment, GOCL and the Hinduja Group complete their strategic exit from the explosives and detonators portfolio. Last y..